The use of intraocular methotrexate to treat uveitis: a safety and efficacy study - Intraocular MTX for uveitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-006728-20-GB

Enrollment

Registered

2007-04-17

Start date

2007-05-31

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveitis (inflammatory eye disease) MedDRA version: 8.1 Level: LLT Classification code 10046851 Term: Uveitis

Interventions

Trade Name: Methotrexate Product Name: Methotrexate Product Code: MTX Pharmaceutical Form: Injection* INN or Proposed INN: Methotrexate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) A diagnosis of uveitis with active disease in one eye only 2) History of intraocular pressure rise in response to corticosteroids 3) Sight-threatening manifestations, either vitritis or cystoid macular oedema Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1) Bilateral active disease 2) Active ocular infection

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine whether intraocular methotrexate is a safe and effective treatment for uveitis in those who are considered unsuitable for intraocular corticosteroids.;Secondary Objective: ;Primary end point(s): Patients will be followed for 2 years post injection, monitoring visual acuity, inflammation, withdrawal of systemic medication and frequency of relapse.	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026